A Phase 1 Trial of Menin-inhibitor Ziftomenib in Combination with Chemotherapy for Children with Relapsed/Refractory KMT2A-r/NUP98-r/NPM1-m Acute Leukemia
The primary objective of the study is to determine the recommended phase 2 dose (RP2D) of ziftomenib in combination with chemotherapy (FLA) in children with relapsed or refractory KMT2A-r, NUP98-r, or NPM1-m acute leukemia based on safety and pharmacokinetics (PK).
100 Clinical Results associated with LLS PedAL Initiative, LLC
0 Patents (Medical) associated with LLS PedAL Initiative, LLC
100 Deals associated with LLS PedAL Initiative, LLC
100 Translational Medicine associated with LLS PedAL Initiative, LLC